Shows
ASCO EducationAddressing Barriers and Leveraging New Technologies in Lung Cancer ScreeningDr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book. 2025-06-0926 minASCO EducationThe Evolution of the ASCO Educational Book and the Issues Shaping the Future of OncologyOn the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPT Dr. Nathan Pennell: Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast, ASCO Education: By the Book. The podcast will feature engaging discussions between editors and authors from the ASCO Educational Book. Each month, you'll hear nu...2025-04-1431 min
ASCO Daily NewsWhat Challenges Will Oncologists Face in 2025?Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. 2025 promises to be a year of continued progress in drug development, patient care, and technological innovations that will shape the future of cancer care. Oncologists will also be grappling...2024-12-0523 min
The Retic LoungeEpisode 116: Species Spotlight | Dwarf Burmese Pythons w/ Michael PennellEpisode 116: Species Spotlight – Dwarf Burmese Pythons (Progschai) with Michael Pennell of Python in a Pear TreeIn this exciting episode of The Retic Lounge, Lucas and Nathan are joined by Michael Pennell of Python in a Pear Tree to spotlight the unique and fascinating world of Dwarf Burmese Pythons, also known as Progschai. Michael, a passionate breeder and keeper, shares his extensive knowledge and experiences working with these stunning, smaller variants of the iconic Burmese Python species. Tune in as we explore the natural history, husbandry, and breeding techniques of Dwarf Burmese Pythons, discussing everything fro...2024-10-251h 54
The Sunday Session with Francesca RudkinJoan's Picks: The Act of Disappearing and Serviceman JThe Act of Disappearing by Nathan Gower. Julia White is struggling - her mother died recently, she’s had a one night stand with an ex and now he’s ghosted her, her first published book is a failure and she’s working in a Brooklyn café. One day, an older guy comes in and shows her a photo taken in the 1960s of a woman falling off a bridge, clutching her baby. Turns out he’s a very famous photographer who actually took that picture behind which he says there’s a mystery and a story which he wants Julia...2024-08-0404 minASCO Daily NewsPutting Patients First: Common Sense in Cancer CareDr. Nathan Pennell and Dr. Christopher Booth discuss Common Sense Oncology, a global initiative that aims to advance patient-centered, equitable care and improve access to treatments that provide meaningful outcomes. TRANSCRIPT Dr. Nate Pennell: Hello. I'm Dr. Nate Pennell, your guest host today for the ASCO Daily News Podcast. I'm the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research at the Taussig Cancer Center, and I also serve as the editor-in-chief of the ASCO Educational Book. My guest today is Dr. Christopher Booth, a professor of oncology and health...2024-07-1825 minASCO Daily NewsASCO24: Transforming the Lung Cancer Treatment LandscapeDrs. Vamsi Velcheti and Nathan Pennell discuss novel approaches and key studies in lung cancer that were showcased at the 2024 ASCO Annual Meeting, including the Plenary abstracts LAURA and ADRIATIC. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health. Today, I'm joined by Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and the vice chair of clinical research a...2024-06-2133 minASCO Daily NewsASCO24: The Era of the ADCs in NSCLCDrs. Vamsi Velcheti and Nathan Pennell discuss key lung cancer abstracts from the 2024 ASCO Annual Meeting, including data from LUMINOSITY and ADAURA, novel therapies in KRASG12C-mutant advanced NSCLC, and the need for effective adjuvant therapies for patients with rare mutations. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic medical oncology at Perlmutter Cancer Center at NYU Langone Health. Today, I'm delighted to welcome Dr. Nathan Pennell, the co-director of the Cleveland Clinic Lung...2024-05-2426 min
Cleveland Clinic Cancer AdvancesSaving Lives and Costs with Next-Generation Sequencing in Non-Small Cell Lung CancerMedical Oncologist and Co-Director of the Lung Cancer Program at Cleveland Clinic, Nathan A. Pennell, MD, PhD joins the Cancer Advances podcast to discuss the study he and his team conducted exploring the potential benefits of transitioning from single-gene testing to next-generation sequencing (NGS). Listen as Dr. Pennell explains the pivotal role genomic testing has in treating lung cancer and the barriers to widespread NGS testing.2023-11-0224 min
Healthcare UnfilteredPitfalls of Clinical Trials: Lessons From ADAURAMaking their return to the show are Drs. Jack West and Nathan Pennell, of City of Hope Comprehensive Cancer Center and Cleveland Clinic, respectively, this time to use the ADAURA trial as a springboard to discussing pitfalls and shortcomings of modern clinical trial designs. The trio go back and forth on control arms keeping pace with standards of care, studies mandating the ability for crossovers, and appropriate endpoints for adjuvant studies. Then, they highlight underwhelming clinical trial data that have led to FDA approvals, whether ADAURA featured a “known inferior agent” and an “inferior crossover design,” and whether ADAURA proved to be an...2023-09-121h 11ASCO Daily NewsAddressing the Impact of Prior Authorization on Access to Cancer TreatmentDrs. Nathan Pennell and Nancy Lin discuss emerging data on the growing problem of prior authorization and insurance denials in cancer care, their potentially harmful impact on patient outcomes, and what can be done to fix the problem. TRANSCRIPT Dr. Nathan Pennell: Hello, I'm Dr. Nathan Pennell, your guest host for the ASCO Daily News Podcast today. I'm the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Institute. More importantly, today, for this podcast, I'm also the editor-in-chief for the ASCO Educational Book. On today's...2023-06-0825 min
Caris Molecular Minute Podcast SeriesInterview with Dr. Nathan Pennell: How Broad NGS Testing Can Save Lives and Potentially Reduce CostsCaris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Nathan Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program and Vice Chair of Clinical Research for the Taussig Cancer Institute. Together they discuss the methodology and results of a recent JCO paper for which Dr. Pennell was a senior author: Modeling Costs and Life-Years Gained by Population-Wide NGS or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the US.
For more information, please visit: www.CarisLifeSciences.com2023-04-0522 min
PeerView Internal Medicine CME/CNE/CPE Video PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Clinical Pharmacology CME/CNE/CPE VideoNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
PeerView Internal Medicine CME/CNE/CPE Audio PodcastNathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLCGo online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhi...2023-02-031h 14
The Ron Flatter Racing PodS6E13: Tips for racetrack foodiesWhere to find good food and drink at or around racetracks. That is the topic for a special panel this week on the Ron Flatter Racing Pod. At the Races host Steve Byk, award-winning turf writer Alicia Hughes, trainer Neil Pessin and sports writer Matt Stahl compare notes on the best restaurants for horseplayers and fans nationwide, including destination restaurants during visits to the Triple Crown. Paddock Prince handicapper David Levitch has tips for weekend races at Aqueduct and Gulfstream Park. The Ron Flatter Racing Pod via Horse Racing Nation is available via free subscription from Apple, Google, Spotify...2023-01-131h 26
Cleveland Clinic Cancer AdvancesKRYSTAL-1 Lung Cancer TrialDirector of the Lung Cancer Medical Oncology Program at Cleveland Clinic Taussig Cancer Institute, Nathan A. Pennell, MD, PhD joins the Cancer Advances podcast to discuss the KRYSTAL-1 trial, a new treatment option for patients with advanced non-small-cell lung cancer with KRASG12C mutation. Listen as Dr. Pennell explains the trial and findings that were presented at the American Society of Clinical Oncology (ASCO) 2022 annual meeting.2022-08-0424 min
The Research EvangelistMeet Dr. Nathan Pennell. Director of Thoracic Oncology at Cleveland Clinic. Compassionate oncologist, proud dad and Pittsburgh Steelers fan.On today's episode, meet Dr. Nathan Pennell. Dr. Pennell is a medical oncologist, and Director of Thoracic Oncology at the Cleveland Clinic. He is also Vice Chair of Clinical Research for the Cleveland Clinic Taussig Cancer Institute. He's a proud dad and Steelers fan, and a really nice guy. I'm proud to have him on my show.2021-09-3048 min
ASCO EducationCancer Topics - Impact of COVID-19 on Clinical ResearchDr. Rodrigo Munhoz (Sírio Libanês Hospital, Brazil) moderates a discussion highlighting the impact that COVID-19 has had on clinical research. Featuring Drs. Nathan Pennell (Cleveland Clinic), Kathryn Mileham (Atrium Health), and patient advocate Dr. Jane Perlmutter. Subscribe: Apple Podcasts, Google Podcasts | Additional resources: education.asco.org | Contact Us Air Date: 9/22/2021 TRANSCRIPT [MUSIC PLAYING] SPEAKER: The purpose of this podcast is to educate and inform. This is not a substitute for medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this pod...2021-09-2226 min
Lung Cancer ConsideredPeer to Peer: Issues, Strategies and Impact with Dr. Nathan PennellIn this episode of Lung Cancer Considered, Dr. Nathan Pennell, from the Cleveland Clinic, and Podcast host Dr. Narjust Duma, from Dana Farber Cancer Institute, share information about how lung cancer care has changed in the 14 years Dr. Pennell has been in practice.2021-09-1842 min
CCO Oncology PodcastExperts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung CancerIn this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLCIncorporating newly approved immunotherapies into practiceEvolving guidelines and recommendations for biomarker testing RNA- vs DNA-based next-generation sequencingInterpretation of NGS resultsUse of frontline TKI therapy for patients with CNS metastasesFuture role of KRAS inhibitors in the treatment of advanced NSCLCImproving rates of biomarker t...2021-05-1927 min
Healthcare UnfilteredBeyond ADAURA: What's Right and What's Wrong With FDA Regulations?Chadi welcomes back Jack West (@JackWestMD), MD, associate clinical professor and medical oncologist, City of Hope Comprehensive Cancer Center, and Nathan Pennell (@n8pennell), MD, PhD, thoracic medical oncologist, director of the thoracic oncology program and director of clinical research, Cleveland Clinic, to the show. The task was to break down the ADAURA trial again, but to go beyond ADUARA and explore the use of various endpoints in lung cancer and how trials should be optimally designed to assure that patients garner the benefits that they deserve. The trio uses this discussion to contextualize a debate on the FDA lowering...2021-02-2354 min
CCO Oncology PodcastExpert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung CanceIn this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistancePerforming biomarker testing on cytology vs surgical or anatomic pathology specimensFactors affecting turnaround time when testing liquid biopsy vs tissue specimensChoice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skippingConcordance between IHC and FISH or NGS for ALK rearrangementsUse...2020-12-2814 min
JCO Oncology Practice PodcastOncologic Services Through Project Access and Other Safety Net Care Coordination ProgramsDr. Pennell and Dr. James Hammock discuss the provision of oncologic services by Project Access safety net care coordination programs. NATHAN PENNELL: Hello, and welcome to the latest JCO Oncology Practice podcast, brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content, and offering enriching insight into the world of cancer care. You can find all recordings, including this one, at podcast.asco.org. My name is Dr. Nate Pennell, medical oncologist at the Cleveland Clinic and consulting editor for the JCO O...2020-11-2320 min
Lung Cancer ConsideredADAURA: A Lively Debate Among Key VoicesThe latest episode of Lung Cancer Considered focuses on the research from the ADAURA trial that came out of ASCO 2020. This episode features a conversation between IASLC Chief Science Officer, Dr. Chandra Belani; Dr. Nathan Pennell, professor of medicine and director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute; Dr. Jack West, an associate clinical professor in medical oncology, a specialist in thoracic oncology and executive director of employee services at City of Hope of Comprehensive Cancer Center; and Jill Feldman, lung cancer patient, patient advocate and co-founder of the group EGFRResisters.2020-07-0640 minJCO Oncology Practice PodcastGender Differences in Faculty Rank and Leadership Positions Among Hematologists and Oncologists in the United StatesDr. Pennell, Dr. Khosa and Dr. Marshall discuss the recent JCO OP publication, “Gender Differences in Faculty Rank and Leadership Positions Among Hematologists and Oncologists in the United States” Welcome to the latest JCO Oncology Practice podcast, brought to you by the ASCO podcast network, a collection of nine programs covering a range of educational and scientific content, and offering enriching insight into the world of cancer care. You can find all recordings, including this one, at podcast.asco.org. my name is Dr. Nate Pennell, Medical Oncologist at the Cleveland Clinic, and consultant editor for t...2020-05-2922 min
VeseliyDJVeseliyDJ - #Stayathome mixtape (Best of future-house)1 Jess Glynne - Don't Be So Hard On Yourself (Hibell Remix)
2 Axwell ? Ingrosso - More Than You Know (Extended Mix)
3 Depdramez & Markhese - Om my own
4 Alex Preston ft. Chris Arnot - Chasing Ghosts (Original Mix)
5 CID - I Miss You (Extended Mix)
6 Dave Ramone feat. Minelli
7 Galantis –Love On Me (MAGNUS Remix)
8 Lucas & Steve feat Mike Williams & Curbi - Lets Go
9 Kungs vs. Cookin on 3 Burners–This Girl (Nathan C Remix)
10 Lucas & Steve vs. Pep & Rash – Enigma (Original Mix)
11 Madison Mars - Theme "O"
12 Mari Ferrari – Hello, Hello (Going Deeper Remix)
13 Madison Mars – Future Is Now
14 Sam Feldt & Deepend feat. Teem...2020-04-301h 09JCO Oncology Practice PodcastImproving the Time to Activation of New Clinical Trials at a National Cancer Institute–Designated Comprehensive Cancer CenterDr. Nathan Pennell, Dr. Muhammed Beg and Ms. Erin Williams discuss improving the time-to-activation of new clinical trials at an NCI-Designated Comprehensive Cancer Center. Read the article: https://ascopubs.org/doi/full/10.1200/OP.19.00325 TRANSCRIPT [PIANO MUSIC PLAYING] DR. PENNELL: Welcome to the latest Journal of Oncology Practice podcast brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all recordings, including this one, at podcast.a...2020-02-0519 minJCO Oncology Practice PodcastDetermining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted TherapiesDr. Nate Pennell discusses "How to Know if a Somatic Tumor Mutation is Targetable" with Suanna Bruinooge, the director of research, strategy, and operations at ASCO's Center for Research and Analytics, or CENTRA, and Dr. Richard Schilsky, senior vice president and chief medical officer at ASCO. Read the related article "Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies." [DR. NATHAN PENNELL] Welcome to the latest Journal of Oncology Practice Podcast brought to you by the ASCO Podcast Network, a collection of nine programs covering a r...2019-09-1023 minJCO Oncology Practice PodcastOncologists’ Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology WorkforceDr. Nathan Pennell and Dr. Jennifer Ligibel discuss weight management and physical activity programs for patients with cancer. TRANSCRIPT: Hello, and welcome to the ASCO Journal of Oncology Practice podcast. This is Dr. Nate Pennell, medical oncologist at the Cleveland Clinic and consultant editor for the JOP. I'm sure everyone who listens to this podcast is aware that obesity and lack of physical activity are major health problems in the USA, and they contribute to multiple medical conditions such as heart disease, diabetes. But how much do patients and oncologists know about how obesity and...2019-06-2718 minJCO Oncology Practice PodcastState of Cancer Care in AmericaDr. Blase Polite discusses the latest State of Cancer Care in America report, and the opportunities and challenges confronting the cancer care community. Read the related article "The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey" on JOP Support for JCO Oncology Practice podcasts is provided in part by AstraZeneca, dedicated to advancing options and providing hope for people living with cancer. More information at AstraZeneca-us.com. Welcome back everyone to the ASCO Journal of Oncology Practice podcast. This is Dr. Nate Pennell, medical oncologist at t...2018-06-2023 minJCO Oncology Practice PodcastOpen Oncology Notes: A Qualitative Study of Oncology Patients’ Experiences Reading Their Cancer Care NotesDr. Nathan Pennell and author Dr. Thomas W. LeBlanc discuss how open notes have become a routine part of the patient experience, and why physicians might want to elicit and address concerns that arise from notes. Read the related article "Open Oncology Notes: A Qualitative Study of Oncology Patients’ Experiences Reading Their Cancer Care Notes" on JOP Support for JCO Oncology Practice podcasts is provided in part by AstraZeneca, dedicated to advancing options and providing hope for people living with cancer. More information at AstraZeneca-us.com. Hello, and welcome back to the ASCO Jo...2018-04-3017 minJCO Oncology Practice Podcast2017 ASCO Quality Care Symposium: Nurturing a New and Growing Community of Practitionersby Dr. Nathan Pennell and Dr. Michael Neuss Related Article: 2017 ASCO Quality Care Symposium: Nurturing a New and Growing Community of Practitioners2017-09-1911 min
PARADISE PARTY with Matt Green[GAY POP] – PARADISE PARTY #74NEW MUSIC from EDX, GENERIK, MASSIVEDRUM, BOB SINCLAR, and more!
And big new remixes from BLONDE, PINK PANDA, MERK & KREMONT, and MED33P!
PLUS heaps more!
PARADISE PARTY – SHOW #74 As first aired on September 14th 2017.
Listen live, download the Podcast, or check out the curated playlist in Spotify! >> http://paradiseparty.com.au
Check out it’s premiere on Thursdays at 4PM, AND repeated before your Saturday night out at 8PM.
Online: http://gayradio.com.au
or via the Mobile Apps: Search ‘GAY POP’ in your app store of choice.
Promo...2017-09-141h 00PARADISE PARTY with Matt Green[MUSIC ONLY] – PARADISE PARTY #74NEW MUSIC from EDX, GENERIK, MASSIVEDRUM, BOB SINCLAR, and more!
And big new remixes from BLONDE, PINK PANDA, MERK & KREMONT, and MED33P!
PLUS heaps more!
PARADISE PARTY – SHOW #74 As first aired on September 14th 2017.
Listen live, download the Podcast, or check out the curated playlist in Spotify! >> http://paradiseparty.com.au
Check out it’s premiere on Thursdays at 4PM, AND repeated before your Saturday night out at 8PM.
Online: http://gayradio.com.au
or via the Mobile Apps: Search ‘GAY POP’ in your app store of choice.
Promo...2017-09-141h 00
GRACEcastPredictive Testing for Chemotherapy ResponsivenessDr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.2016-02-2003 minGRACEcastHER2 Mutation Positive NSCLCDr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.2016-02-1902 minGRACEcastALK Inhibitors for Acquired Resistance: Zykadia and AlectinibDr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.2016-02-1803 minGRACEcastCombinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLCDr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.2016-02-1704 minGRACEcastThird Generation EGFR TKIs for Acquired ResistanceDr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.2016-02-1703 minGRACEcastTargeted Therapies in a Post-Operative/Adjuvant SettingDr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.2016-02-1103 minJCO Oncology Practice PodcastJOP Announces New Look and FeelJournal of Oncology Practice Associate Editor Apar Ganti talks with Consultant Editor Nathan Pennell about what readers can expect to see in the pages of JOP starting in 2016.2016-01-1304 min
Cancer.Net Podcast2015 ASCO Educational Book - Using Social Media to Learn and Communicate about Cancer, with Michael A. Thompson, MD, PhD and Nathan A. Pennell, MD, PhD In this podcast, Dr. Michael Thompson discusses his article, “Using Social Media to Learn and Communicate: It Is Not About the Tweet” with Dr. Nathan Pennell. Cancer Research News 2015-11-1010 min
Cancer.Net Podcasts2015 ASCO Educational Book - Using Social Media to Learn and Communicate about Cancer, with Michael A. Thompson, MD, PhD and Nathan A. Pennell, MD, PhD In this podcast, Dr. Michael Thompson discusses his article, “Using Social Media to Learn and Communicate: It Is Not About the Tweet” with Dr. Nathan Pennell. Cancer Research News 2015-11-1010 min
GRACEcastClinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer PatientsDr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival. http://bit.ly/NCIALCHEMIST2015-11-0604 minJCO Oncology Practice PodcastBarriers to Prescribing Crizotinib Following FDA Approvalby Robert S. Miller, MD. Dr. Nathan Pennell discusses some of the interesting obstacles he encountered when trying to prescribe crizotinib for 3 patients with ALK positive non-small cell lung cancer in the first few weeks following FDA approval in 2011.2012-07-1028 min
STUPID LUNG CANCERSURVIVOR SPOTLIGHT
MATTHEW HIZNAY
Young Adult Survivor, Lung Cancer
Second Year Med Student
University of Toldeo
NATHAN PENNELL, MD, PhD
Board Certified Oncologist
Taussig Cancer Center
Cleveland Clinic
KATE BROWN
Director of Support and Advocacy
LUNGevity Foundation2012-03-131h 12
The Stupid Cancer ShowSTUPID LUNG CANCERSURVIVOR SPOTLIGHT
MATTHEW HIZNAY
Young Adult Survivor, Lung Cancer
Second Year Med Student
University of Toldeo
NATHAN PENNELL, MD, PhD
Board Certified Oncologist
Taussig Cancer Center
Cleveland Clinic
KATE BROWN
Director of Support and Advocacy
LUNGevity Foundation
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.2012-03-131h 11
GRACEcast Lung Cancer AudioQ and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (audio)Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.2010-03-0714 min
GRACEcast Lung Cancer VideoQ and A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (video)Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.2010-03-0714 minGRACEcast Lung Cancer AudioThe Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (audio)
Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.
2010-01-3035 min
GRACEcast Lung Cancer VideoThe Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (video)Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.2010-01-3035 min